Thiazolyl and pyridyl aminoalcohols

ABSTRACT

COMPOUNDS OF THE FORMULA   (R7,R8-PHENYL)-CH(-OH)-CH(-R6)-NH-CH2-CH(-R5)-Y-X(-R1)   (-R2)(-R3)(-R4)   THEIR SALTS AND QUARTENARY AMMONIUM COMPOUNDS, AS WELL AS THEIR OPTICALLY ACTIVE ISOMERS OR DIASTEREOMERS WHEREIN R1 TO R4 REPRESEN HYDROGEN, HALOGEN, LOWER ALKYL, ARALKYL, PHENYL, HYDROXYL, LOWER ALKOXY, NITRO OR LOWER CARBOALKOXY, R5 AND R6 ARE HYDROGEN OR METHYL, R7 AND R8 ARE HYDROGEN, HALOGEN OR LOWER ALKOXY, X IS A HETEROCYCLIC RING SYSTEM, MONO- OR CONDENSED BYCYCLIC, WITH 1-4 HETERO ATOMS, IN WHICH THE INDIVIDUAL RINGS HAVE 5 TO 6 MEMBERS AND CAN ALSO CONTAIN 1 OR MORE CRBONYL GROUPS, Y IS -CO- OR -CH(OH)-. THESE COMPOUNDS HAVE PHARMACOLOGICAL ACTIVITY IN THAT THEY INCREASE THE CORONARY BLOOD FLOW BY SIMULTANEOUSLY CAUSING DILATION OF THE CORONARIES AND AN INCREASE IN CONTRACTION STRENGTH.

United States Patent Olfice 3,631,055 THIAZOLYL AND PYRIDYL AMINOALCOHOLS Klaus Posselt, Bergen-Enkheim, and Kurt Thiele, Frankfurt am Main, Germany, assignors to Deutsche Goldund Silber-Scheideanstalt vormals Roessler, Frankfurt am Main, Germany No Drawing. Continuation-impart of application Ser. No. 693,138, Dec. 26, 1967. This application Mar. 10, 1970, Ser. No. 18,279 The portion of the term of the patent subsequent to May 26, 1987, has been disclaimed Int. Cl. C07d 31/42 US. Cl. 260-296 R 4 Claims ABSTRACT OF THE DISCLOSURE Compounds of the formula their salts and quartenary ammonium compounds, as well as their optically active isomers or diastereomers wherein R to R represent hydrogen, halogen, lower alkyl, aralkyl, phenyl, hydroxyl, lower alkoxy, nitro or lower carboalkoxy, R and R are hydrogen or methyl, R and R are hydrogen, halogen or lower alkoxy, X is a heterocyclic ring system, monoor condensed bicyclic, with 1-4 hetero atoms, in which the individual rings have 5 to 6 members and can also contain 1 or more carbonyl groups, Y is -CO or -CH(OH). These compounds have pharmacological activity in that they increase the coronary blood flow by simultaneously causing dilation of the coronaries and an increase in contraction strength.

This application is a continuation-in-par-t of application Ser. No, 693,138, filed Dec. 26, 1967, now Pat. 3,514,465.

DETAILED DESCRIPTION OF THE INVENTION INCLUDING PREFERRED EMBODIMENTS The following heterocyclic ring systems, for example, come into consideration for the compounds according to the invention: furane, thiophene, pyrrole, pyrazole, thiazole, pyridine, pyrimidine, triazine, pyrazolone, benzofurane, benzothiophene, indole, quinoline, isoquinoline, benzodioxol, benzodioxane, decahydroisoquinoline, benzothiazole and benzimidazole.

The compounds according to the invention of the above Formula I can be produced in a known manner by (a) Reacting a compound of the formula \)|(C -011 la 1'1 R (II) with a compound of the formula R7 H,N on o11 l u R (III) in the presence of formaldehyde or a formaldehyde source and a solvent.

(b) Reacting a compound of the formula 2 o o-C=0H, Ii in R IV or the corresponding Mannich base of the formula 3,631,552 Patented Dec. 28, 1971 with a compound of the formula in which W and V are different and are either halogen or NH in the presence of a basic substance and, if desired, in the event Y is CO, reducing such group to a CH(OH) group and, if desired, converting the bases produced into their'pharmacologically acceptable acid addition salts or quaternary ammonium salts.

The process according to method (a) is carried out in the usual manner at a temperature between 20 and 150 C. Alcohols, dioxane, glacial acetic acid and the like come into consideration as solvents.

The process according to method (b) in general when using an unsaturated ketone of Formula IV can be carried out at temperatures between 20 and C. in an inert solvent, such as, ether, acetone, dioxane or chloroform, whereas when the corresponding Mannich base is used, which during the reaction is transformed into an intermediate of Formula IV, the reaction temperature used is normally higher, preferably, between 80 and C., and solvents such as water, alcohol/water, or a two phase system such as benzene/water toluene/water come into consideration.

The process according to method (0) is usually carried out at elevated temperatures in a solvent such as alcohols, ether, dimethyl formamide and the like.

The compounds produced which contain optically active carbon atoms and which as a rule are produced as racemates can be resolved into their optically active isomers in the usual manner, for example, with the aid of an optically active acid. It, however, is also possible to employ optically active compounds or diastereomers as the starting materials whereby the end product in the corresponding pure optically active form or diastereomeric configuration is obtained.

The free bases can be converted into their salts with the usual pharmacologically acceptable acids such as HCl, HBr, H 80 acetic acid, citric acid, succinic acid, maleic acid, fumaric acid, lactic acid, p-toluene sulfonic acid and the like. Those compounds containing basic tertiary nitrogen atoms can be converted to their quaternary salts with the usual pharmacologically acceptable quaternizing agents such as the lower alkyl halides. The free bases can be removed from the salts, for example, by treatment with aqueous NaOH and other salts can be prepared from such free bases.

As already indicated, the compounds according to the invention have a pharmacological activity in that they increase the coronary blood fiow by causing dilation of the coronaries, as well as an increase in contraction strength of the heart.

3 When tested on the isolated guinea pig heart according to Langendorff (Pfliigers Arch. 61, 291, 1895) it was found that the compounds according to the invention were active in doses between IO-SOOag/heart (,ug.='y=microgram) in dilating the coronaries while simultaneously increasing the contraction strength.

The indications for the compounds according to the invention are:

Coronary insufiiciency Angina pectoris Myocardial infarct Myocardial insufiiciency Circulatory disturbances of various gcneses Disturbances of the peripheral and cerebral blood flow Migraines Arteriosclerosis The novel compounds can be used, if desired, also in combination with other medicaments in the form of pharmaceutical composition suited for enteral, parenteral, oral or per lingual application.

The acute toxicity of the compounds according to the invention when tested on mice by the method of Miller and Tainter (Proc. Soc. exper. Biol. a Med. 57, 261, 1944) expressed as the LD 50 is between 100 mg./kg. and 5000 mg./kg. oral.

The individual doses for human beings, depending on form of administration are between 0.5 and 100 mg., once or more times a day.

The following examples will serve to illustrate the compounds according to the invention. For sake of simplicity the symbol of Z is used in the structural formulae and nomenclature of a number of the examples to represent, respectively CH and (2-[3-phenyl-3hydroxy-propyl-(2-amino]-ethyl EXAMPLE 1 1 [2 phenyl-3-hydroxy-propyl-(Z-amino-ethyl} thienyl-(Z-ketone, that is, 1-{Z}-thienyl-(2)-ketone Method (a).12.6 g. (0.1 mol) of 2 acetyl-thiophene, 18.7 g. (0.1 mol) of l-norephedrine-HCl and 4 g. (0.13 mol) of paraformaldehyde were dissolved in 20 ml. of isopropanol and after addition of 0.2 mol of concentrated HCl boiled under reflux for 2 hours. Thereafter 100 ml. of acetone were added to the still warm solution. The hydrochloride which crystallized out upon cooling was purified by recrystallization from ethanol. Its melting point was 191-192 C. and the yield 17 g.

Method (b).1.5 g. (0.01 mol) of l-norephedrine were dissolved in 50 ml. of ether and 2.7 g. (0.02 mol) of thienyl vinyl ketone dissolved in ml. of ether added thereto. After /2 hour 2 g. of the base separated out which after recrystallization from ethanol had a melting point of 118120 C. The hydrochloride produced therefrom had a melting point of 19ll92 C.

Method (c).--5.2 g. (0.03 mol) of Z-[fl-chloropropinoyl]-thiophene were dissolved in dimethyl formamide and united with a solution of 4.5 g. (0.03 mol) of l-norephedrine and 4 g. (0.03 mol) of triethylamine in 25 ml. of dimethyl formamide. After 1 hour the triethylamine HCl which was formed was filtered off and the filtrate acidified with isopropanolic HCl. Subsequently, the HCl salt was precipitated from the solution by addition of ether and recrystallized from ethanol. Its melting point was l9ll92 C. and the yield was 7 g.

.4 EXAMPLE 2 1-{Z}-phenol-(2)-ketone 11 g. (0.1 mol) of Z-acetyI-furan, 18.7 g. (0.1 mol) of l-norephedrine-HCI and 4 g. (0.13 mol) of paraformaldehyde were heated for 2 hours under reflux in 20 ml. of isopropanol with the addition of 5 drops of ethanolic HCl. The HCl salt which had precipitated out was stirred up with 50 ml. of acetone and filtered off. It was purified by recrystallization from ethanol. Its melting point was 186- 187 C. and the yield was 10.5 g.

EXAMPLE 3 1-{Z}- [-methyl-thiazolyl- (2-ketone 7 g. (0.05 mol) of 4-methyl-2-acetyl-thiazole, 9.4 g. (0.05 mol) of l-norephedrine-HCI, 2 g. (0.067 mol) of paraformaldehyde and 5 drops of isopropanolic HCl in 20 ml. of isopropanol were reacted and processed as in Example 2. The HCl salt was recrystallized from methanol. Its melting point was 197-199 C. and the yield 7 g.

EXAMPLE 4 l-{Z}-antipyry1-(4)-ketone C5H5 OH -III C=O CH;C=-COZ 11.5 g. of 4-acetyl-antipyrin (0.05 mol), 9.5 g. of 1- norephedrineHCl .(0.05 mol) and 2 g. of paraformaldehyde (0.067 mol) were introduced into 20 ml. of iso propanol and 5 drops of isopropanolic HCl added thereto and the mixture boiled for a total of 5 hours during which after 3 hours an additional 1 g. of paraformaldehyde was added. Thereafter the solvent was distilled off and the residue treated with aqueous soda. The oily Mannich base produced was crystallized with the aid of ether. It formed the dihydrochloride with 2 mol of HCl which was recrystallized from ethanol. Its melting point was 206208 C. and the yield was 9 g.

EXAMPLE 5 1-{Z}-pyridy1-(3)-ketone COZ 40 g. (0.33 mol) of 3-acetyl-pyridine, 18.7 g. (0.1 mol) of l-norephedrine-HCI and '3 g. (0.1 mol) of paraformaldehyde were boiled under reflux in 15 ml. of isopropanol for a total of 3 hours. An additional 1 g. of paraformaldehyde was added after 1 hour. Thereafter the reaction mixture was diluted with acetone and the precipitated HCl salt was recrystallized from methanol/ethanol (1:2). Its melting point was 187-l89 C. and the yield 7 g.

EXAMPLE 6 1-{Z}-[2,4-dimethyl-thiazolyl- (5 -ketone NI CH3 CHQl l0 0 Z S 25 g. (0.16 mol) of 2,4-dimethyl-5-acetyl-thiazole, 30 g. (0.16 mol) of l-norephedrine-HCI and 5 g. (0.16 mol) of paraformaldehyde were introduced into 50 ml. of isopropanol and 15 drops of isopropanolic HCl added thereto. The mixture was boiled on a water bath for a total of 1 hour. An additional 1.5 g. of paraformaldehyde was added after /2 hour. The reaction solution was diluted with 100 ml. of acetone while still warm. The HCl salt Whlch precipitated out was recrystallized from 80% (ethanol. Its melting point was 208210 C. and the yield EXAMPLE 7 5 g. (0.035 mol) of 4-methyl-2-hydroxy-5-acetylthiazole, 6.6 g. (0.035 mol) of l-norephedrine-HCI and 1.5 g. (0.05 mol) of paraformaldehyde were boiled under reflux for 2 hours in 20 ml. of glacial acetic acid. The HCl salt which crystallized out On cooling was recrystallized from methanol/ethanol (1: 1). Its melting point was 209- 210 C. and the yield 4.5 g.

EXAMPLE 8 1-{Z}-cumaronyl-ketone 40 g. (0.25 mol) of 2-acetyl cumarone, 46.5 g. (0.25 mol) of l-norephedrine-HCl and 7.5 g. (0.25 mol) of paraformaldehyde were dissolved in 200 ml. of isoamyl alcohol and after addition of 10' drops of ethanolic-HCI boiled under reflux for /2 hour. Then an additional 2.5 g. (0.083 mol) of paraformaldehyde were added and the mixture refluxed for a further A hour. The solution was diluted with 100 ml. of acetone while still warm. Upon cooling the HCl salt crystallized out. It was recrystallized from ethanol. Its melting point was 199-200 C. and the yield 31.5 g.

EXAMPLE 9 1-3-{3-[3-phenyl-3-hydroxy-propyl-(2)-amino]- propionyl}-thionaphthene 17.6 g. (0.1 mol) of 3-acetyl-thionaphthene, 18.7 g. (0.1 mol) of l-norephedrine-HCI and 4.5 g. (0.15 mol) of paraformaldehyde were boiled under reflux for 2 hours in 0 m1. of isopropanol. The solution was then diluted with 100 ml. of acetone while still warm. Upon cooling the HCl salt precipitated out. It was recrystallized from methanol. Its melting point was 220-221 C. and the yield 18.5 g.

COZ

EXAMPLE 10 1-3-{3-[3-phenyl-3-hydroxy-propyl-(2)-amino]- propionyl}-l-methyl-indole COZ tallized from ethanol. Its melting point was 194195 C. and the yield 22 g.

EXAMPLE 11 1-5-{3- [3-phenyl-3-hydroxy-propyl-(2)-amino]- propionyl}-benzodioxol- 1,3

8 g. (0.048 mol) of 5-acetyl-henzodioxol-(1,3), 9.1 g. (0.048 mol) of l-norephedrine-HCI and 2.9 g. (0.097 mol) of paraformaldehyde were boiled on a water bath for 2 hours in 30 ml. of isopropanol after addition of 5 drops of isopropanolic HCl. After addition of ml. of acetone to the warm reaction solution, the HCl salt precipitated out. It was recrystallized from ethanol. Its melting point was 195-197 C. and the yield 9 g.

EXAMPLE 12 1 4 {3 [Ii-phenyl-3-hydroxy-propyl-(2)-amino]-propionyl} 1,3 dimethyl and -l,5 dimethyl pyrazole (mixture) riii N N (EH.

26 g. (0.19 mol) of the isomeric mixture of 1,3- and 1,5-dimethyl-4-acetyl-pyrazole formed during the synthesis, 37.4 g. (0.2 mol) of l-norephedrine-HCl and 9 g. (0.3 mol) of paraformaldehyde were boiled under reflux under an atmosphere of nitrogen in ml. of isopropanol for 3 hours. Upon cooling the HCl salt crystallized. It was recrystallized from isopropanol and then twice from ethanol. Its melting point was 196 C. and the yield 11 g.

EXAMPLE 13 1-{Z}-quinolyl- (3 -ketone 1-{Z}-isoquinolyl- (4) -ketone 5 g. (0.024 mol) of 4-acetyl isoquinoline-HCl, 4.6 g. (0.024 mol) of l-norephedrine-HCI and 0.7 g. (0.024 mol) of paraformaldehyde were boiled on a water bath for 2.5 hours in 50 ml. of a 1:1 mixture of ethanol-isopropanol and an additional 0.4 g. (0.012 mol) of paraformaldehyde was added after 1 hours boiling. Upon cooling, the dihydrochloride salt precipitated out. It was recrystallized from ethanol. Its melting point was 208 C. and the yield 3 g.

7 EXAMPLE 15 1- {Z} 1,2,4-trimethyl-carbethoxypyrrolyl- (3 ]-ket0ne 18 g. (0.081 mol) of 1,2,4-trimethyl-3acetyl-5-carhethoxypyrrole, 15.2 g. (0.081 mol) of l-norephedrin-HCl and 2.4 g. (0.081 mol) of paraformaldehyde were boiled on a water bath for 1.5 hours in 50 ml. of isopropanol. An additional 1.2 g. of paraformaldehyde were added after /2 hours boiling. Upon addition of 100 ml. of acetone the HCl salt precipitated out. It was recrystallized from ethanol. Its melting point was 178-180 C. and the yield g.

EXAMPLE 16 1-6-{ 3-[3phenyl-3-hydr0xy-propyl-(2)amino] propionyl}-benzodioxane-( 1,4)

was recrystallized from ethanol. Its melting point was 201 C. and the yield 7.5 g.

EXAMPLE 17 1-2- 3- 3-phenyl-3 hydroxy-propyl- 2 amino] propionyl}-benzodioxane-(1,4)

o Too-z 0 11 g. (0.061 mol) of 2-acetyl-1,4-benzodioxane, 11.6 g. (0.062 mol) of l-norephedrine-I-ICl and 1.85 g. (0.062 mol) of paraformaldehyde were reacted in 30 ml. of

isopropanol and processed as in Example 16. The melting point of the HCl salt was 178 C. and the yield 8 g.

EXAMPLE 18 1-{Z}-[2-benzyl-10-hydroxy-decahydroisoquinolyl- (4) ]-ketone 11 g. (0.0339 mol) of 2-benzyl-4-acetyl-lO-hydroxydecahydroisoquinoline-HCl, 6.5 g. (0.035 mol) of l-norephedrine-HCI and 1.4 g. (0.047 mol) of paraformaldehyde were boiled on a water bath for 2 hours in 35 ml. of isopropanol. An additional 1.4 g. of paraformaldehyde were added after 1 hours boiling. The solvent was then distilled off and acetone and ethyl acetate added to the residue. The dihydrochloride produced was recrystallized from ethanol. Its melting point was 182l83 C. and the yield 7 g.

EXAMPLE 19 1-{Z}-[5-nitro-furyl-(2) ]-ketone 8 11.6 g. (0.075 mol) of Z-acetyl-S-nitro-furane, 14 g. (0.075 mol) of l-norephedrine-HCI and 3 g. (0.1 mol) of paraformaldehyde in 50 ml. of isopropanol were heated on a water bath for 3 hours. The HCl salt which precipitated out upon cooling was recrystallized from ethanol. Its melting point was 210 C. and the yield 3 g.

EXAMPLE 20 1-4- 3- 3-phenyl-3hydroxy-propyl- 2 amino pr0pionyl}-1,3,5-trimethyl pyrazole 27 g. (0.178 mol) of 1,3,5trimethyl-4-acetylpyrazole, 33 g. (0.177 mol) of 1-norephedrine-HCl and 10.8 g. (0.36 mol) of paraformaldehyde in 150 ml. of isopropanol were heated for 2 hours on a water bath. Thereafter the solvent was distilled off and ml. acetone were added to the residue. The HCl salt which precipitated was recrystallized from isopropanol. Its melting point was 191 C. and the yield was 14.5 g.

EXAMPLE 21 1-4-{3- 3phenyl-3hydroxy-propyl- (2 amino] propi- 0nyl}-lbenzyl-3,S-dimethyl-pyrazole 13.5 g. (0.0624 mol) of 3,5-dimethyl-1-benzyl-4-acetylpyrazole, 11.1 g. (0.0593 mol) of l-norephedrine-HCI and 3.6 g. (0.12 mol) of paraformaldehyde were heated on a water bath in 200 ml. of isopropanol for 2 hours. The HCl salt precipitated out from the reaction solution after addition of 100 ml. of acetone and it was recrystallized from ethanol. Its melting point was 200 C. and the yield 11 g.

EXAMPLE 22 d,l-{2- 3- (3 fluoro-4-methoxy-phenyl -3-hydroxy-propy1- (2)-amino]ethyl}-thienyl-(2)-ketone 28 g. (0.119 mol) of d,l-3-(3fiuoro-4-n1ethoxy-phenyl)- 3-hydroxy-propyl-(2)amine-HCI, 15 g. (0.119 mol) of 2-acetyl-thiophene and 7.2 g. (0.24 mol) of paraformaldehyde were reacted in 200 ml. of isopropanol and processed as in Example 21. The HCl salt was recrystallized from ethanol. Its melting point was 208 C. and the yield was 10 g.

EXAMPLE 23 1-{1- [3 phenyl-3-hydroxy-propyl- (2 amino] propyl- (2) }-thienyl-(2) ketone 43 g. (0.307 mol) of 2-propionylthiophene, 57.7 g. (0.308 mol) of l-norephedrine-HCI and 18.4 g. (0.614 mol) of paraformaldehyde were heated on a water bath in 50 ml. of isopropanol for 1 hour. 100 ml. of acetone were added to the reaction solution and the HCl salt which precipitated out recrystallized from ethanol. Its melting point was 208 C. and the yield was 16.5 g.

9 EXAMPLE 24 1- {Z}.--chloro-thienyl- (2 )-ketone 30 g. (0.187 mol) of 2-acetyl-5-chloro-thiophene, 35 g. (0.187 mol) of l-norephedrine'HCl and 5.6 g. (0.187 mol) of paraformaldehyde were heated in 50 ml. of isopropanol and processed as in Example 21. The HCl salt was recrystallized from ethanol. Its melting point was 198 C. and the yield was 16 g.

EXAMPLE 25 d, l -{2- 2-(2-chloro-phenyD-Z-hydroxy-ethylamino] ethyl}- thieny1-(2)-ketone EXAMlPLE 26 [3 -phenyl-3 -hydroxy-propyl- 2) 3- [4-phenyl-thiazolyl- (2) ]-3-hydroxy-propyl- 1 }-amine 6 g. (0.015 mol) of 1-{Z}-[4-phenyl-thiazolyl-(2)]- ketone-HCl were suspended in 60 ml. of methanol and reduced by the addition of 0.6 g. (0.016 mol) of sodium borohydride. After 1 hour the solvent was distilled ofl? and the residue dissolved in acetone. Fumaric acid was added to such solution to precipitate out the fumarate salt. The base was again set free from the fumarate with aqueous NaOH. The resulting oily base was taken up in ether and converted to the HCl salt with isopropanolic HCl and such salt recrystallized from ethanol. Its melting point was 178-181 C. and the yield was 2.5 g.

EXAMPLE 27 [3-phenyl-3-hydroxypropyl- (2) ]-{3- [thienyl- (2) -3 hydroxy-propyl- 1 )}-amine ugJ-CH-oH-z 63 g. (0.2 mol) of 1-{Z}-thienyl-(2)-ketone-HCl and 300 g. of aluminum isopropylate were heated to 130 C. for 2 hours in 2 liters of isopropanol and the acetone produced during the reduction distilled off over a column. After 7 hours the cooled solution was decomposed by addition of 100 g. of citric acid in 200 ml. of water and then rendered strongly alkaline with aqueous NaOH. The organic phase was dried over calcium oxide and the solvent distilled oif under vacuum. The amino alcohol product melted at 123-125 C. after it was recrystallized from 50% ethanol. Upon addition of an equimolar quantity of HCl a HCl salt was obtained which had a melting point of 152-155 C. The yield was 13 g.

10 EXAMPLE 28 [3-phenyl-3-hydroxy-propyl- (2) ]-{3- [cumaronyl- (2) 3-hydroxy-propyl- 1 }-amine 18 g. (0.05 mol) of 1-{Z}-cumaronyl-ketone-HCl were suspended in ml. of ethanol and reduced at room temperature with 2 g. of sodium borohydride dissolved in 50 ml. of ethanol. After 1 hour, 50 ml. of concentrated HCl were added and the NaCl produced filtered off. The solvent was then distilled 01f under vacuum and the residue recrystallized from isopropanol/ethyl acetate (1:1). The HCl salt produced melted at 210-215 C. with decomposition. The yield was 11 g.

EXAMPLE 29 [3 -phenyl-3-hydroXy-propyl- (2) 3-thionaphthenyl- (3) ]-3-hydroxy-propyl- 1 }-amine CHOH-- K/ S Z EXAMPLE 30 l-phenyl-l-hydroxypropyl- 2) 1- [4-methylthiazolyl- (2) ]-1-hydroxypropy1-(3 ]-amine 15 g. (0.044 mol) of [2- [-l-phenyl-l-hydroxypropyl- ('2) amino] -ethyl] [4-methy1-thiazolyl- (2) ]ketone HCl were reduced with .1 g. of sodium boranate in ml. of methanol at room temperature. After standing overnight, the mixture was acidified with concentrated HCl, the solvent distilled olf and the residue extracted with boiling ethanol. The HCl salt crystallized upon cooling. Its melting point was 201-202" C. and the yield was 5.5 g.

EXAMPLE 31 [l-phenyl-l-hydroxypropyl- (2) 1- 2,4-dimethyl-thiazolyl- (5 1 -1-hydroxypropyl- 3 -amine 10.7 g. (0.03 mol) of [2-[l-phenyl-l-hydroxypropyl- (2) amino]-ethyl]-[2,4-dimethyl thiazolyl (5)]-ketone-HCl were reduced with 1 g. of sodium boranate in 100 ml. of methanol and worked up as in Example 30. The HCl salt had a melting point of 217-218 C. and the yield was 5 g.

EXAMPLE 32 [l-pyridyl- 3 l -hydroxypropyl-( 3) l-phenyl- 1- hydroxy pro pyl- (2) J-amine 23 g. of 1-[2-[3-phenyl-3-hydroxypropyl-(2)-amino]- ethyl]-pyridyl-(3)-ketone-HC1 were dissolved in 250 ml. of ethanol and hydrogenated in the presence of 0.7 g. of platinum oxide at room temperature and normal pressure until the calculated amount of hydrogen was taken up. After filtering olf the catalyst the solvent was removed by distillation and the HCl salt remaining behind was recrystallized from isopropanol-acetone (one part to two parts). The melting point was 161 C. and the yield was 7.5 g.

The compounds of Examples 30, 31 and 32 not only increase the coronary blood flow as pointed out supra, but also have a very good activity against disturbances in peripheral and cerebral blood flow.

12 What is claimed is: 1. A compound selected from the group consisting of (a) l-phenyl-l-hydroxypropy1-( 2) l-[4-methyl-thiazolyl( 2) l-hydroxypropyl-(3 ]-amine, (b) [1-phenyl-1-hydroxypropy1-(2) 1- [2,4-dimethylthiazolyl-(S) ]-1-hydroxypropyl-(3) ]-amine, and (c) [1-pyridyl-(3)-l-hydroxypropyl-(3)]-[1-phenyl-1- hydroxypropyl- 2) ]-amine. 2. A compound according to claim 1 having Formula a.

3. A compound according to claim 1 having Formula b.

4. A compound according to claim 1 having Formula c.

References Cited UNITED STATES PATENTS 3,514,465 5/1970 Posselt et al. 260-296 NORMA S. MILESTONE, Primary Examiner S. D. WINTERS, Assistant Examiner US. Cl. X.R. 260302 R 

